Selecta Biosciences, Inc. (SELB) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
65 GROVE STREET WATERTOWN, MA 02472 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 134,602 | 128,055 | 138,685 | 89,893 | 37,403 | 96,562 | |||
| Cash and cash equivalents | 106,438 | 114,057 | 138,685 | 89,893 | 37,403 | 70,622 | |||
| Short-term investments | 28,164 | 13,998 | 25,940 | ||||||
| Restricted cash and investments | 289 | 279 | 76 | ||||||
| Receivables | 6,596 | 9,914 | 7,224 | 5,000 | 63 | ||||
| Contract with customer, asset, after allowance for credit loss | 3,162 | ✕ | |||||||
| Other undisclosed current assets | 3,489 | 6,474 | 5,434 | 1,495 | 4,673 | 1,979 | |||
| Total current assets: | 148,138 | 144,443 | 151,343 | 96,667 | 42,076 | 98,680 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 11,617 | 9,829 | 10,948 | 301 | ✕ | ✕ | |||
| Property, plant and equipment | 2,794 | 2,142 | 1,395 | 1,222 | 2,127 | 2,091 | |||
| Restricted cash and investments | 1,311 | 1,379 | 1,379 | 1,379 | 279 | 329 | |||
| Other undisclosed noncurrent assets | 2,026 | 2,090 | 370 | ||||||
| Total noncurrent assets: | 17,748 | 15,440 | 14,092 | 2,902 | 2,406 | 2,420 | |||
| TOTAL ASSETS: | 165,886 | 159,883 | 165,435 | 99,569 | 44,482 | 101,100 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 14,400 | 11,358 | 8,589 | 13,992 | 12,800 | 10,186 | |||
| Taxes payable | ✕ | ✕ | 601 | ||||||
| Accounts payable | 316 | 224 | 443 | 500 | 1,100 | 1,606 | |||
| Accrued liabilities | 14,084 | 10,533 | 8,146 | 13,492 | 11,700 | 8,580 | |||
| Deferred revenue | 593 | 53,883 | 72,050 | 1,674 | ✕ | ✕ | |||
| Debt | 8,476 | 5,961 | 19,277 | 21,385 | |||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 787 | ||
| Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | ✕ | 959 | ✕ | ||
| Other undisclosed current liabilities | 1,608 | 1,049 | 908 | ||||||
| Total current liabilities: | 25,077 | 72,251 | 81,547 | 34,943 | 35,144 | 10,973 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 17,786 | 28,271 | 34,440 | 21,042 | |||||
| Long-term debt, excluding current maturities | 17,786 | 19,673 | 24,793 | 21,042 | |||||
| Liabilities, other than long-term debt | 10,055 | 11,417 | 38,746 | 14,680 | 14,756 | 17,271 | |||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 16,070 | ||
| Deferred revenue | 11,417 | 38,746 | 14,680 | ✕ | ✕ | ||||
| Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | ✕ | 13,818 | ✕ | ||
| Deferred rent credit | 34 | ✕ | |||||||
| Other liabilities | 904 | 1,201 | |||||||
| Operating lease, liability | 10,055 | 8,598 | 9,647 | ✕ | ✕ | ||||
| Other undisclosed noncurrent liabilities | 19,140 | 25,423 | 28,708 | 41,549 | |||||
| Total noncurrent liabilities: | 46,981 | 65,111 | 101,894 | 56,229 | 14,756 | 38,313 | |||
| Total liabilities: | 72,058 | 137,362 | 183,441 | 91,172 | 49,900 | 49,286 | |||
| Equity | |||||||||
| Equity, attributable to parent | 93,828 | 22,521 | (18,006) | 8,397 | (5,418) | 51,814 | |||
| Common stock | 15 | 12 | 11 | 9 | 3 | 3 | |||
| Additional paid in capital | 493,308 | 457,391 | 391,175 | 348,664 | 279,539 | 273,128 | |||
| Accumulated other comprehensive loss | (4,558) | (4,566) | (4,563) | (4,523) | (4,557) | (4,420) | |||
| Accumulated deficit | (394,937) | (430,316) | (404,629) | (335,753) | (280,403) | (216,897) | |||
| Total equity: | 93,828 | 22,521 | (18,006) | 8,397 | (5,418) | 51,814 | |||
| TOTAL LIABILITIES AND EQUITY: | 165,886 | 159,883 | 165,435 | 99,569 | 44,482 | 101,100 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 110,777 | 85,077 | 16,597 | 6,677 | 903 | 207 | ||
| Gross profit: | 110,777 | 85,077 | 16,597 | 6,677 | 903 | 207 | ||
| Operating expenses | (96,239) | (89,674) | (73,418) | (59,132) | (65,925) | (63,991) | ||
| Operating income (loss): | 14,538 | (4,597) | (56,821) | (52,455) | (65,022) | (63,784) | ||
| Nonoperating income (expense) | 2,381 | 59 | 405 | (519) | 1,180 | 342 | ||
| Investment income, nonoperating | 2,073 | 44 | 260 | 834 | 1,050 | 617 | ||
| Gain (loss), foreign currency transaction, before tax | (22) | 56 | (47) | 120 | (123) | |||
| Other nonoperating income (expense) | 330 | 15 | 89 | (1,306) | 10 | (152) | ||
| Interest and debt expense | (3,031) | (2,844) | (2,017) | (1,519) | (1,494) | (1,879) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | 13,888 | (7,382) | (58,433) | (54,493) | (65,336) | (65,321) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 20,882 | (2,339) | ||||||
| Income (loss) from continuing operations before income taxes: | 34,770 | (9,721) | (58,433) | (54,493) | (65,336) | (65,321) | ||
| Income tax expense (benefit) | 609 | (15,966) | ||||||
| Income (loss) from continuing operations: | 35,379 | (25,687) | (58,433) | (54,493) | (65,336) | (65,321) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (25,687) | (58,433) | (54,493) | (65,336) | (65,321) | |
| Net income (loss): | 35,379 | (25,687) | (58,433) | (54,493) | (65,336) | (65,321) | ||
| Other undisclosed net income (loss) attributable to parent | (10,443) | (857) | ||||||
| Net income (loss) attributable to parent: | 35,379 | (25,687) | (68,876) | (55,350) | (65,336) | (65,321) | ||
| Other undisclosed net income available to common stockholders, basic | ||||||||
| Net income (loss) available to common stockholders, diluted: | 35,379 | (25,687) | (68,876) | (55,350) | (65,336) | (65,321) | ||
Comprehensive Income ($ in thousands)
| 9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 35,379 | (25,687) | (58,433) | (54,493) | (65,336) | (65,321) | ||
| Other comprehensive loss | (137) | |||||||
| Comprehensive income (loss): | 35,379 | (25,687) | (58,433) | (54,493) | (65,473) | (65,321) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 8 | (3) | (10,483) | (823) | 98 | |||
| Comprehensive income (loss), net of tax, attributable to parent: | 35,387 | (25,690) | (68,916) | (55,316) | (65,473) | (65,223) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.